Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
The Journal of Reproduction and Development|September 17, 2014
Uterine glycogen metabolism in mink during estrus, embryonic diapause and pregnancyMatthew Dean, Jason Hunt, Lisa McDougall, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 29, 2017
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass EffectGuillaume P Nicolas, Rosalba Mansi, Lisa McDougall, et al.Pharmaceuticals (Basel, Switzerland)|April 3, 2021
SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and SpacersRaghuvir Haridas Gaonkar, Fabius Wiesmann, Luigi Del Pozzo, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 StudyChristopher Eigler, Lisa McDougall, Andreas Bauman, et al.EJNMMI Physics|August 27, 2025
Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imagingFrida Westerbergh, Lisa McDougall, Philipp Ritt, et al.Psychopharmacology|August 17, 2004
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsJohn H Krystal, Walid Abi-Saab, Edward Perry, et al.Frontiers in Nuclear Medicine|October 28, 2024
Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical studyTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.EJNMMI Research|April 6, 2024
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b studyChristof Rottenburger, Michael Hentschel, Markus Fürstner, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2019
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a StudyChristof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2024
61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human ImagingTais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, et al.Pageof 2